UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 21, 2019

 

CANCER GENETICS, INC.

(Exact Name of Company as Specified in its Charter)

 

Delaware   001-35817   04-3462475
(State or Other Jurisdiction
of Incorporation)
 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

201 Route 17 North 2nd Floor, Rutherford, New Jersey 07070

(Address of Principal Executive Offices) (Zip Code)

 

Company’s telephone number, including area code (201) 528-9200

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   CGIX   The Nasdaq Capital Market

 

 

 

 
 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

Loan from Atlas Sciences, LLC

 

On October 21, 2019, Cancer Genetics, Inc. (the “Company” or “CGIX”) entered into a Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued a promissory note (the “Note”) to Atlas Sciences, LLC, an institutional accredited investor (the “Investor”) in the initial principal amount of $1,347,500. The Investor gave consideration of $1,250,000, reflecting original issue discount of $87,500 and expenses payable by the Company of $10,000. The Company has used all of the proceeds from the Note for partial repayment of the past due convertible promissory note dated July 17, 2018 (the “Iliad Note”) from Iliad Research and Trading, L.P., an affiliate of the Investor.

 

The Note is the general unsecured obligation of the Company. Interest accrues on the outstanding balance of the Note at 10% per annum, and the Note has a 12-month term. Upon the occurrence of an event of default, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. The Note contains customary default provisions, including provisions for potential acceleration.

 

The Investor may redeem any portion of the Note, at any time after six months from the issue date upon three business days’ notice, subject to a maximum monthly redemption amount of $300,000. The Company may prepay the outstanding balance of the Note, in part or in full without penalty.

 

The foregoing description is qualified in its entirety by reference to the full text of the Note and the Purchase Agreement, a copy of each of which is filed as Exhibit 4.1 and Exhibit 10.1 hereto, and each of which is incorporated herein by reference.

 

Settlement Agreement with NovellusDx Ltd.

 

In connection with the signing on September 18, 2018 of a merger agreement (the “Merger Agreement”) with NovellusDx Ltd. (“NDX”), the Company on such date also entered into a Credit Agreement (the “Credit Agreement”) with NDX, pursuant to which NDX made a loan to the Company in the amount of $1,500,000, evidenced by a promissory note dated the same date (the “NDX Note”).

 

The Credit Agreement was the general unsecured obligation of the Company, carried an interest rate of 10.75% per annum and provided that amounts owed by the Company to NDX under the Credit Agreement must be repaid if the Merger Agreement was terminated in accordance with its terms (or 90 days thereafter in the case of certain causes for such termination). The Merger Agreement was terminated in December 2018. Thereafter, the Company did not repay the amounts owed under the Credit Agreement when due.

 

On October 21, 2019, the Company and NDX entered into a Settlement Agreement (the “Settlement Agreement”), pursuant to which the Company (a) paid NDX $100,000 upon entering into the Settlement Agreement, (b) agreed to pay NDX $1,000,000 on the fifth business day after the Company receives at least $5,000,000 from Interpace Diagnostics Group, Inc. (“IDXG”) pursuant to the Excess Consideration Note issued by IDXG to the Company in connection with its acquisition of the Company’s BioPharma business (the date such payment of $1,000,000 is made, the “One Million Payment Date”), and (c) agreed to pay NDX $50,000 per month for nine months ($450,000 in the aggregate) commencing one month after the One Million Payment Date.

 

In addition, pursuant to the Settlement Agreement, upon the One Million Payment Date, the Credit Agreement and the NDX Note will be amended, among other things, to reduce the total amount due thereunder to the abovementioned $450,000 obligation, to be interest free, to mature nine months after the One Million Payment Date, to provide for the conversion feature described below and otherwise as provided in the Settlement Agreement. Upon a default by the Company in any payment against the $450,000 obligation, NDX has the right to convert all, but not less than all, unpaid amounts under the amended Credit Agreement and NDX Note to common stock of the Company at a price of $0.15 per share.

 

Additionally, upon the Company’s making the $1,000,000 payment, each party will release the other from all claims under the Credit Agreement, the NDX Note, the Merger Agreement and related documents other than the Company’s obligation to make the payments against the $450,000 obligation.

 

The foregoing description is qualified in its entirety by reference to the full text of the Settlement Agreement, a copy of which is filed as Exhibit 10.2 hereto, and which is incorporated herein by reference.

 

-2-
 

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Company.

 

The information set forth above in Item 1.01 of this Report with respect to the Note Purchase Agreement, the Note and the Settlement Agreement is incorporated herein by reference.

 

Item 3.02. Unregistered Sales of Equity Securities.

 

The information set forth above in Item 1.01 of this Report with respect to the Settlement Agreement is incorporated herein by reference.

 

Item 7.01. Regulation FD Disclosure.

 

As the result of the previously announced sale of the Company’s BioPharma business to Interpace Diagnostics Group, Inc. (Nasdaq: IDXG) or its affiliate, IDXG or its affiliate paid approximately $6 million in cash to CGIX on October 24, 2019, as partial settlement of a promissory note in the original face amount of approximately $7.7 million due to CGIX. The gross purchase price of the BioPharma sale transaction was $23.5 million less certain closing adjustments totaling approximately $2.0 million, in addition to the assumption by IDXG of approximately $5.2 million of liabilities relating to the BioPharma business. IDXG or its affiliate paid approximately $9.25 million in cash at closing to the company’s former senior secured lenders, and the balance of the cash portion of the purchase price of approximately $2.25 million (net of expenses) was paid to the company. IDXG’s subsidiary also issued a promissory note to CGIX in the original face amount of approximately $7.7 million, subject to certain post-closing adjustments and holdbacks. The note was due upon the approval by IDXG’s shareholders of a significant investment by Ampersand Capital Partners in IDXG and the closing of that investment, which occurred on October 16, 2019. The payment of approximately $6 million represents amounts known to be due at this date. After known post-closing reductions of approximately $0.8 million, the company may receive up to an additional $0.9 million in January 2020 or thereafter, subject to certain contingencies and set-off rights of IDXG.

 

On October 24, 2019, the Company issued a press release announcing the engagement of H.C. Wainwright & Co. LLC. A copy of the press release is furnished as Exhibit 99.1 hereto and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 

Forward-Looking Statements

 

This report, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements typically are identified by use of terms such as “may,” “will,” “should,” “plan,” “expect,” “anticipate,” “estimate” and similar words, and the opposites of such words, although some forward-looking statements are expressed differently. Forward-looking statements involve known and unknown risks and uncertainties that exist in the Company’s operations and business environment, which may be beyond the Company’s control, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. For example, forward-looking statements include, without limitation: statements regarding prospects for future transactions; and other financial information; and plans, strategies and objectives of management for future operations. The risks and uncertainties referred to above include, but are not limited to, risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2018 and its Quarterly reports on Form 10-Q for the quarters ended March 31 and June 30, 2019. These risks could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company. Forward-looking statements represent the judgment of management of the Company regarding future events. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable at the time that they are made, the Company can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable law, the Company assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

As described above, the following exhibits are furnished as part of this report:

 

Exhibit 4.1 —Promissory Note with Atlas Sciences.

 

Exhibit 10.1 — Note Purchase Agreement with Atlas Sciences.

 

Exhibit 10.2 — Settlement Agreement with NovellusDx Ltd.

 

Exhibit 99.1 — Press Release, dated October 24, 2019

 

-3-
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CANCER GENETICS, INC.
     
  By: /s/ John A. Roberts
  Name:  John A. Roberts
  Title: President and Chief Executive Officer
     
Date:  October 24, 2019    

 

-4-
 

 

PROMISSORY NOTE

 

Effective Date: October 21, 2019 U.S. $1,347,500.00

 

FOR VALUE RECEIVED, Cancer Genetics, Inc., a Delaware corporation (“Borrower”), promises to pay to Atlas Sciences, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $1,347,500.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is twelve (12) months after the Purchase Price Date (the “Maturity Date”) in accordance with the terms set forth herein and to pay interest on the Outstanding Balance at the rate of ten percent (10%) per annum from the Purchase Price Date until the same is paid in full. All interest calculations hereunder shall be computed on the basis of a 360-day year comprised of twelve (12) thirty (30) day months, shall compound daily and shall be payable in accordance with the terms of this Note. This Promissory Note (this “Note”) is issued and made effective as of October 21, 2019 (the “Effective Date”). This Note is issued pursuant to that certain Note Purchase Agreement dated October 21, 2019, as the same may be amended from time to time, by and between Borrower and Lender (the “Purchase Agreement”). Certain capitalized terms used herein are defined in Attachment 1 attached hereto and incorporated herein by this reference.

 

This Note carries an OID of $87,500.00. In addition, Borrower agrees to pay $10,000.00 to Lender to cover Lender’s legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale of this Note (the “Transaction Expense Amount”), all of which amount is fully earned and included in the initial principal balance of this Note. The purchase price for this Note shall be $1,250,000.00 (the “Purchase Price”), computed as follows: $1,347,500.00 original principal balance, less the OID, less the Transaction Expense Amount. The Purchase Price shall be payable by Lender by wire transfer of immediately available funds.

 

1. Payment; Prepayment.

 

1.1. Payment. All payments owing hereunder shall be in lawful money of the United States of America and delivered to Lender at the address or bank account furnished to Borrower for that purpose. All payments shall be applied first to (a) costs of collection, if any, then to (b) fees and charges, if any, then to (c) accrued and unpaid interest, and thereafter, to (d) principal.

 

1.2. Prepayment. Borrower may pay all or any portion of the amount owed earlier than it is due without penalty.

 

2. Security. This Note is unsecured.

 

3. Redemption. Beginning on the date that is six (6) months after the Purchase Price Date, Lender shall have the right, exercisable at any time in its sole and absolute discretion, to redeem any amount of this Note up to $300,000.00 (such amount, the “Redemption Amount”) per calendar month by providing written notice to Borrower (each, a “Redemption Notice”). For the avoidance of doubt, Lender may submit to Borrower one (1) or more Redemption Notices in any given calendar month so long as the aggregate amount being redeemed in such month does not exceed $300,000.00. Upon receipt of any Redemption Notice, Borrower shall pay the applicable Redemption Amount in cash to Lender within three (3) business days of Borrower’s receipt of such Redemption Notice.

 

 
 

 

4. Defaults and Remedies.

 

4.1. Defaults. The following are events of default under this Note (each, an “Event of Default”): (a) Borrower fails to pay any principal, interest, fees, charges, or any other amount when due and payable hereunder; (b) a receiver, trustee or other similar official shall be appointed over Borrower or a material part of its assets and such appointment shall remain uncontested for twenty (20) days or shall not be dismissed or discharged within sixty (60) days; (c) Borrower becomes insolvent or generally fails to pay, or admits in writing its inability to pay, its debts as they become due, subject to applicable grace periods, if any, or waivers; (d) Borrower makes a general assignment for the benefit of creditors; (e) Borrower files a petition for relief under any bankruptcy, insolvency or similar law (domestic or foreign); (f) an involuntary bankruptcy proceeding is commenced or filed against Borrower; (g) Borrower or any pledgor, trustor, or guarantor of this Note defaults or otherwise fails to observe or perform (after giving effect to any grace periods) any covenant, obligation, condition or agreement of Borrower or such pledgor, trustor, or guarantor contained herein or in any other Transaction Document (as defined in the Purchase Agreement), other than those specifically set forth in this Section 4.1 and Section 4 of the Purchase Agreement; (h) any representation, warranty or other statement made or furnished by or on behalf of Borrower or any pledgor, trustor, or guarantor of this Note to Lender herein, in any Transaction Document, or otherwise in connection with the issuance of this Note is false, incorrect, incomplete or misleading in any material respect when made or furnished; (i) the occurrence of a Fundamental Transaction without Lender’s prior written consent unless 100% of the Outstanding Balance due on this Note is paid in full in connection with such Fundamental Transaction; (j) any United States money judgment, writ or similar process is entered or filed against Borrower or any subsidiary of Borrower or any of its property or other assets for more than $1,000,000.00, and shall remain unvacated, unbonded or unstayed for a period of twenty (20) calendar days unless otherwise consented to by Lender; (k) Borrower fails to observe or perform any covenant set forth in Section 4 of the Purchase Agreement; or (l) Borrower, any affiliate of Borrower, or any pledgor, trustor, or guarantor of this Note breaches any material covenant or other term or condition contained in any Other Agreements (after giving effect to any grace periods therein or waivers thereof). Notwithstanding the foregoing, the occurrence of any event described in Section 4.1(a) shall not be considered an Event of Default if such event is cured within five (5) days of the occurrence of such event and the occurrence of any event described in Sections 4.1(g) – (l) above shall not be considered an Event of Default hereunder if such event is cured within fifteen (15) days of the occurrence of such event.

 

4.2. Remedies. At any time and from time to time after Lender becomes aware of the occurrence of any Event of Default, Lender may accelerate this Note by written notice to Borrower, with the Outstanding Balance becoming immediately due and payable in cash at the Mandatory Default Amount. Notwithstanding the foregoing, at any time following the occurrence of any Event of Default, Lender may, at its option, elect to increase the Outstanding Balance by applying the Default Effect (subject to the limitation set forth below) via written notice to Borrower without accelerating the Outstanding Balance, in which event the Outstanding Balance shall be increased as of the date of the occurrence of the applicable Event of Default pursuant to the Default Effect, but the Outstanding Balance shall not be immediately due and payable unless so declared by Lender (for the avoidance of doubt, if Lender elects to apply the Default Effect pursuant to this sentence, it shall reserve the right to declare the Outstanding Balance immediately due and payable at any time and no such election by Lender shall be deemed to be a waiver of its right to declare the Outstanding Balance immediately due and payable as set forth herein unless otherwise agreed to by Lender in writing). Notwithstanding the foregoing, upon the occurrence of any Event of Default described in clauses (b), (c), (d), (e) or (f) of Section 4.1, the Outstanding Balance as of the date of acceleration shall become immediately and automatically due and payable in cash at the Mandatory Default Amount, without any written notice required by Lender. At any time following the occurrence of any Event of Default, upon written notice given by Lender to Borrower, interest shall accrue on the Outstanding Balance beginning on the date the applicable Event of Default occurred at an interest rate equal to the lesser of twenty-two percent (22%) per annum or the maximum rate permitted under applicable law (“Default Interest”). In connection with acceleration described herein, Lender need not provide, and Borrower hereby waives, any presentment, demand, protest or other notice of any kind, and Lender may immediately and without expiration of any grace period enforce any and all of its rights and remedies hereunder and all other remedies available to it under applicable law. Such acceleration may be rescinded and annulled by Lender at any time prior to payment hereunder and Lender shall have all rights as a holder of the Note until such time, if any, as Lender receives full payment pursuant to this Section 4.2. No such rescission or annulment shall affect any subsequent Event of Default or impair any right consequent thereon. Nothing herein shall limit Lender’s right to pursue any other remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.

 

 
 

 

5. Unconditional Obligation; No Offset. Borrower acknowledges that this Note is an unconditional, valid, binding and enforceable obligation of Borrower not subject to offset, deduction or counterclaim of any kind. Borrower hereby waives any rights of offset it now has or may have hereafter against Lender, its successors and assigns, and agrees to make the payments called for herein in accordance with the terms of this Note.

 

6. Waiver. No waiver of any provision of this Note shall be effective unless it is in the form of a writing signed by the party granting the waiver. No waiver of any provision or consent to any prohibited action shall constitute a waiver of any other provision or consent to any other prohibited action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or commit a party to provide a waiver or consent in the future except to the extent specifically set forth in writing.

 

7. [Reserved].

 

8. Opinion of Counsel. In the event that an opinion of counsel is needed for any matter related to this Note, Lender has the right to have any such opinion provided by its counsel.

 

9. Governing Law; Venue. This Note shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of Utah, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Utah. The provisions set forth in the Purchase Agreement to determine the proper venue for any disputes are incorporated herein by this reference.

 

10. Arbitration of Disputes. By its issuance or acceptance of this Note, each party agrees to be bound by the Arbitration Provisions (as defined in the Purchase Agreement) set forth as an exhibit to the Purchase Agreement.

 

11. Cancellation. After repayment of the entire Outstanding Balance, this Note shall be deemed paid in full, shall automatically be deemed canceled, and shall not be reissued.

 

12. Amendments. The prior written consent of both parties hereto shall be required for any change or amendment to this Note.

 

13. Assignments. Borrower may not assign this Note without the prior written consent of Lender. This Note may be offered, sold, assigned or transferred by Lender without the consent of Borrower, so long as such transfer is in accordance with applicable federal and state securities laws.

 

14. Notices. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with the subsection of the Purchase Agreement titled “Notices.”

 

15. Liquidated Damages. Lender and Borrower agree that in the event Borrower fails to comply with any of the terms or provisions of this Note, Lender’s damages would be uncertain and difficult (if not impossible) to accurately estimate because of the parties’ inability to predict future interest rates, future share prices, future trading volumes and other relevant factors. Accordingly, Lender and Borrower agree that any fees, balance adjustments, Default Interest or other charges assessed under this Note are not penalties but instead are intended by the parties to be, and shall be deemed, liquidated damages.

 

16. Severability. If any part of this Note is construed to be in violation of any law, such part shall be modified to achieve the objective of Borrower and Lender to the fullest extent permitted by law and the balance of this Note shall remain in full force and effect.

 

[Remainder of page intentionally left blank; signature page follows]

 

 
 

 

IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed as of the Effective Date.

 

    BORROWER:
       
    Cancer Genetics, Inc.
       
    By:             
    Name:   
    Title:  

 

ACKNOWLEDGED, ACCEPTED AND AGREED:

 

LENDER:

 

Atlas Sciences, LLC    
       
By:  Iliad Research and Trading, L.P., its Manager    
       
By: Iliad Management, LLC, its General Partner    
       
By: Fife Trading, Inc., its Manager    
                         
By:      
  John M. Fife, President    

 

[Signature Page to Promissory Note]

 

 
 

 

ATTACHMENT 1

DEFINITIONS

 

For purposes of this Note, the following terms shall have the following meanings:

 

A1. “Default Effect” means multiplying the Outstanding Balance as of the date the applicable Event of Default occurred by 15% and then adding the resulting product to the Outstanding Balance as of the date the applicable Event of Default occurred, with the sum of the foregoing then becoming the Outstanding Balance under this Note as of the date the applicable Event of Default occurred; provided that the Default Effect may only be applied with respect to one (1) Event of Default.

 

A2. “Fundamental Transaction” means that (a) (i) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, consolidate or merge with or into (whether or not Borrower or any of its subsidiaries is the surviving corporation) any other person or entity, or (ii) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of its respective properties or assets to any other person or entity, or (iii) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, allow any other person or entity to make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of the outstanding shares of voting stock of Borrower (not including any shares of voting stock of Borrower held by the person or persons making or party to, or associated or affiliated with the persons or entities making or party to, such purchase, tender or exchange offer), or (iv) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with any other person or entity whereby such other person or entity acquires more than 50% of the outstanding shares of voting stock of Borrower (not including any shares of voting stock of Borrower held by the other persons or entities making or party to, or associated or affiliated with the other persons or entities making or party to, such stock or share purchase agreement or other business combination), or (b) any “person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act and the rules and regulations promulgated thereunder) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding voting stock of Borrower.

 

A3. “Mandatory Default Amount” means the Outstanding Balance following the application of the Default Effect.

 

A4. “OID” means an original issue discount.

 

A5. “Other Agreements” means, collectively, (a) all existing and future agreements and instruments between, among or by Borrower (or an affiliate), on the one hand, and Lender (or an affiliate), on the other hand, and (b) any financing agreement or a material agreement that affects Borrower’s ongoing business operations.

 

A6. “Outstanding Balance” means as of any date of determination, the Purchase Price, as reduced or increased, as the case may be, pursuant to the terms hereof for payment, offset, or otherwise, plus the OID, the Transaction Expense Amount, accrued but unpaid interest, collection and enforcements costs (including attorneys’ fees) incurred by Lender, transfer, stamp, issuance and similar taxes and fees incurred under this Note.

 

A7. “Purchase Price Date” means the date the Purchase Price is delivered by Lender to Borrower.

 

[Remainder of page intentionally left blank]

 

 
 

 

 

 

Note Purchase Agreement

 

This Note Purchase Agreement (this “Agreement”), dated as of October 21, 2019, is entered into by and between Cancer Genetics, Inc., a Delaware corporation (“Company”), and Atlas Sciences, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”).

 

A. Company and Investor are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the Securities Act of 1933, as amended (the “1933 Act”), and the rules and regulations promulgated thereunder by the United States Securities and Exchange Commission (the “SEC”).

 

B. Investor desires to purchase and Company desires to issue and sell, upon the terms and conditions set forth in this Agreement, a Promissory Note, in the form attached hereto as Exhibit A, in the original principal amount of $1,347,500.00 (the “Note”).

 

C. This Agreement, the Note, and all other certificates, documents, agreements, resolutions and instruments delivered to any party under or in connection with this Agreement, as the same may be amended from time to time, are collectively referred to herein as the “Transaction Documents”.

 

NOW, THEREFORE, in consideration of the above recitals and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Company and Investor hereby agree as follows:

 

1. Purchase and Sale of Note.

 

1.1. Purchase of Note. Company hereby agrees to issue and sell to Investor and Investor hereby agrees to purchase from Company the Note. In consideration thereof, Investor agrees to pay the Purchase Price (as defined below) to Company.

 

1.2. Form of Payment. On the Closing Date (as defined below), Investor shall pay the Purchase Price to Company via wire transfer of immediately available funds in accordance with the Flow of Funds schedule attached hereto as Exhibit B against delivery of the Note.

 

1.3. Closing Date. Subject to the satisfaction (or written waiver) of the conditions set forth in Section 5 and Section 6 below, the date of the issuance and sale of the Note pursuant to this Agreement (the “Closing Date”) shall be October 21, 2019, or another mutually agreed upon date. The closing of the transactions contemplated by this Agreement (the “Closing”) shall occur on the Closing Date by means of the exchange by email of .pdf documents, but shall be deemed for all purposes to have occurred at the offices of Hansen Black Anderson Ashcraft PLLC in Lehi, Utah.

 

1.4. Collateral for the Note. The Note shall be unsecured.

 

1.5. Original Issue Discount; Transaction Expense Amount. The Note carries an original issue discount of $87,500.00 (the “OID”). In addition, Company agrees to pay $10,000.00 to Investor to cover Investor’s legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale of the Note (the “Transaction Expense Amount”), all of which amount is included in the initial principal balance of the Note. The “Purchase Price”, therefore, shall be $1,250,000.00, computed as follows: $1,347,500.00 initial principal balance, less the OID, less the Transaction Expense Amount.

 

  1  
 

 

2. Investor’s Representations and Warranties. Investor represents and warrants to Company that as of the Closing Date: (i) this Agreement has been duly and validly authorized; (ii) this Agreement constitutes a valid and binding agreement of Investor enforceable in accordance with its terms; (iii) Investor is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D of the 1933 Act; and (iv) Investor has been given the opportunity to ask questions and receive answers concerning the terms and conditions of the offering of and to obtain any additional information which Company possesses or can acquire without unreasonable effort or expense that is necessary to verify the accuracy of the information provided to Investor.

 

3. Company’s Representations and Warranties. Company represents and warrants to Investor that as of the Closing Date: (i) Company is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation and has the requisite corporate power to own its properties and to carry on its business as now being conducted; (ii) Company is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary; (iii) Company has registered its shares of common stock, $0.0001 par value per share (the “Common Stock”), under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “1934 Act”), and is obligated to file reports pursuant to Section 13 or Section 15(d) of the 1934 Act; (iv) each of the Transaction Documents and the transactions contemplated hereby and thereby, have been duly and validly authorized by Company and all necessary corporate actions have been taken; (v) this Agreement, the Note, and the other Transaction Documents have been duly executed and delivered by Company and constitute the valid and binding obligations of Company enforceable in accordance with their terms; (vi) the execution and delivery of the Transaction Documents by Company and the consummation by Company of the other transactions contemplated by the Transaction Documents do not and will not conflict with or result in a breach by Company of any of the terms or provisions of, or constitute a default under (a) Company’s formation documents or bylaws, each as currently in effect, (b) any indenture, mortgage, deed of trust, or other material agreement or instrument to which Company is a party or by which it or any of its properties or assets are bound, including, without limitation, any listing agreement for the Common Stock, or (c) any existing applicable law, rule, or regulation or any applicable decree, judgment, or order of any court, United States federal, state or foreign regulatory body, administrative agency, or other governmental body having jurisdiction over Company or any of Company’s properties or assets; (vii) no further authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization, or stock exchange or market or the stockholders or any lender of Company is required to be obtained by Company for the issuance of the Note to Investor or the entering into of the Transaction Documents; (viii) none of Company’s filings with the SEC since January 1, 2017 contained, at the time they were filed, any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading; (ix) since January 1, 2017, Company has filed all reports, schedules, forms, statements and other documents required to be filed by Company with the SEC under the 1934 Act on a timely basis or has received a valid extension of such time of filing and has filed any such report, schedule, form, statement or other document prior to the expiration of any such extension; (x) except for the shareholder suit disclosed in the Company’s SEC filings, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board or body pending or, to the knowledge of Company, threatened against or affecting Company before or by any governmental authority or non-governmental department, commission, board, bureau, agency or instrumentality or any other person, wherein an unfavorable decision, ruling or finding would have a material adverse effect on Company or which would adversely affect the validity or enforceability of, or the authority or ability of Company to perform its obligations under, any of the Transaction Documents; (xi) Company has not consummated any financing transaction that has not been disclosed in a periodic filing or current report with the SEC under the 1934 Act; (xii) Company is not, nor has it been at any time in the previous twelve (12) months, a “Shell Company,” as such type of “issuer” is described in Rule 144(i)(1) under the 1933 Act; (xiii) with respect to any commissions, placement agent or finder’s fees or similar payments that will or would become due and owing by Company to any person or entity as a result of this Agreement or the transactions contemplated hereby (“Broker Fees”), any such Broker Fees will be made in full compliance with all applicable laws and regulations and only to a person or entity that is a registered investment adviser or registered broker-dealer; (xiv) Investor shall have no obligation with respect to any Broker Fees or with respect to any claims made by or on behalf of other persons for fees of a type contemplated in this subsection that may be due in connection with the transactions contemplated hereby and Company shall indemnify and hold harmless each of Investor, Investor’s employees, officers, directors, stockholders, managers, agents, and partners, and their respective affiliates, from and against all claims, losses, damages, costs (including the costs of preparation and attorneys’ fees) and expenses suffered in respect of any such claimed or existing Broker Fees; (xv) neither Investor nor any of its officers, directors, members, managers, employees, agents or representatives has made any representations or warranties to Company or any of its officers, directors, employees, agents or representatives except as expressly set forth in the Transaction Documents and, in making its decision to enter into the transactions contemplated by the Transaction Documents, Company is not relying on any representation, warranty, covenant or promise of Investor or its officers, directors, members, managers, employees, agents or representatives other than as set forth in the Transaction Documents; (xvi) Company acknowledges that the State of Utah has a reasonable relationship and sufficient contacts to the transactions contemplated by the Transaction Documents and any dispute that may arise related thereto such that the laws and venue of the State of Utah, as set forth more specifically in Section 7.2 below, shall be applicable to the Transaction Documents and the transactions contemplated therein; and (xvii) Company has performed due diligence and background research on Investor and its affiliates including, without limitation, John M. Fife, and, to its satisfaction, has made inquiries with respect to all matters Company may consider relevant to the undertakings and relationships contemplated by the Transaction Documents including, among other things, the following: http://investing.businessweek.com/research/stocks/people/person.asp?personId=7505107&ticker=UAHC;SEC Civil Case No. 07-C-0347 (N.D. Ill.); SEC Civil Action No. 07-CV-347 (N.D. Ill.); and FINRA Case #2011029203701. Company, being aware of the matters described in subsection (xvii) above, acknowledges and agrees that such matters, or any similar matters, have no bearing on the transactions contemplated by the Transaction Documents and covenants and agrees it will not use any such information as a defense to performance of its obligations under the Transaction Documents or in any attempt to avoid, modify or reduce such obligations.

 

  2  
 

 

4. Company Covenants. Until all of Company’s obligations under the Note are paid and performed in full, or within the timeframes otherwise specifically set forth below, Company will at all times comply with the following covenants: (i) Company will timely file on the applicable deadline all reports required to be filed with the SEC pursuant to Sections 13 or 15(d) of the 1934 Act, and will take all reasonable action under its control to ensure that adequate current public information with respect to Company, as required in accordance with Rule 144 of the 1933 Act, is publicly available, and will not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would permit such termination; (ii) the Common Stock shall be listed or quoted for trading on any of (a) NYSE, (b) NASDAQ, (c) OTCQX, or (d) OTCQB; and (iii) Company will not enter into any financing transaction with John Kirkland or any of his affiliated entities.

 

5. Conditions to Company’s Obligation to Sell. The obligation of Company hereunder to issue and sell the Note to Investor at the Closing is subject to the satisfaction, on or before the Closing Date, of each of the following conditions:

 

5.1. Investor shall have executed this Agreement and delivered the same to Company.

 

5.2. Investor shall have delivered the Purchase Price to Company in accordance with Section 1.2 above.

 

6. Conditions to Investor’s Obligation to Purchase. The obligation of Investor hereunder to purchase the Note at the Closing is subject to the satisfaction, on or before the Closing Date, of each of the following conditions, provided that these conditions are for Investor’s sole benefit and may be waived by Investor at any time in its sole discretion:

 

6.1. Company shall have executed this Agreement and the Note and delivered the same to Investor.

 

6.2. Company shall have delivered to Investor a fully executed Secretary’s Certificate substantially in the form attached hereto as Exhibit C evidencing Company’s approval of the Transaction Documents.

 

6.3. Company shall have delivered to Investor fully executed copies of all other Transaction Documents required to be executed by Company herein or therein.

 

7. Miscellaneous. The provisions set forth in this Section 7 shall apply to this Agreement, as well as all other Transaction Documents as if these terms were fully set forth therein; provided, however, that in the event there is a conflict between any provision set forth in this Section 7 and any provision in any other Transaction Document, the provision in such other Transaction Document shall govern.

 

7.1. Arbitration of Claims. The parties shall submit all Claims (as defined in Exhibit D) arising under this Agreement or any other Transaction Document or any other agreement between the parties and their affiliates or any Claim relating to the relationship of the parties to binding arbitration pursuant to the arbitration provisions set forth in Exhibit D attached hereto (the “Arbitration Provisions”). For the avoidance of doubt, the parties agree that the injunction described in Section 7.3 below may be pursued in an arbitration that is separate and apart from any other arbitration regarding all other Claims arising under the Transaction Documents. The parties hereby acknowledge and agree that the Arbitration Provisions are unconditionally binding on the parties hereto and are severable from all other provisions of this Agreement. By executing this Agreement, Company represents, warrants and covenants that Company has reviewed the Arbitration Provisions carefully, consulted with legal counsel about such provisions (or waived its right to do so), understands that the Arbitration Provisions are intended to allow for the expeditious and efficient resolution of any dispute hereunder, agrees to the terms and limitations set forth in the Arbitration Provisions, and that Company will not take a position contrary to the foregoing representations. Company acknowledges and agrees that Investor may rely upon the foregoing representations and covenants of Company regarding the Arbitration Provisions.

 

  3  
 

 

7.2. Governing Law; Venue. This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the internal laws of the State of Utah, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Utah. Each party consents to and expressly agrees that the exclusive venue for arbitration of any dispute arising out of or relating to any Transaction Document or the relationship of the parties or their affiliates shall be in Salt Lake County, Utah. Without modifying the parties’ obligations to resolve disputes hereunder pursuant to the Arbitration Provisions, for any litigation arising in connection with any of the Transaction Documents, each party hereto hereby (i) consents to and expressly submits to the exclusive personal jurisdiction of any state or federal court sitting in Salt Lake County, Utah, (ii) expressly submits to the exclusive venue of any such court for the purposes hereof, and (iii) waives any claim of improper venue and any claim or objection that such courts are an inconvenient forum or any other claim, defense or objection to the bringing of any such proceeding in such jurisdiction or to any claim that such venue of the suit, action or proceeding is improper. Finally, Company covenants and agrees to name Investor as a party in interest in, and provide written notice to Investor in accordance with Section 7.11 below prior to bringing or filing any action (including without limitation any filing or action against any person or entity that is not a party to this Agreement) that is related in any way to the Transaction Documents or any transaction contemplated herein or therein, and further agrees to timely name Investor as a party to any such action. Company acknowledges that the governing law and venue provisions set forth in this Section 7.2 are material terms to induce Investor to enter into the Transaction Documents and that but for Company’s agreements set forth in this Section 7.2 Investor would not have entered into the Transaction Documents.

 

7.3. Specific Performance. Company acknowledges and agrees that Investor may suffer irreparable harm in the event that Company fails to perform any material provision of this Agreement or any of the other Transaction Documents in accordance with its specific terms. It is accordingly agreed that Investor shall be entitled to one or more injunctions to prevent or cure breaches of the provisions of this Agreement or such other Transaction Document and to enforce specifically the terms and provisions hereof or thereof, this being in addition to any other remedy to which Investor may be entitled under the Transaction Documents, at law or in equity. Company specifically agrees that following an Event of Default (as defined in the Note) under the Note, Investor shall have the right to seek and receive injunctive relief from a court or an arbitrator prohibiting Company from issuing any of its common or preferred stock to any party unless the Note is being paid in full simultaneously with such issuance. Company specifically acknowledges that Investor’s right to obtain specific performance constitutes bargained for leverage and that the loss of such leverage would result in irreparable harm to Investor. For the avoidance of doubt, in the event Investor seeks to obtain an injunction from a court or an arbitrator against Company or specific performance of any provision of any Transaction Document, such action shall not be a waiver of any right of Investor under any Transaction Document, at law, or in equity, including without limitation its rights to arbitrate any Claim pursuant to the terms of the Transaction Documents, nor shall Investor’s pursuit of an injunction prevent Investor, under the doctrines of claim preclusion, issues preclusion, res judicata or other similar legal doctrines, from pursuing other Claims in the future in a separate arbitration.

 

7.4. Counterparts. Each Transaction Document may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. The parties hereto confirm that any electronic copy of another party’s executed counterpart of a Transaction Document (or such party’s signature page thereof) will be deemed to be an executed original thereof.

 

7.5. Document Imaging. Investor shall be entitled, in its sole discretion, to image or make copies of all or any selection of the agreements, instruments, documents, and items and records governing, arising from or relating to any of Company’s loans, including, without limitation, this Agreement and the other Transaction Documents, and Investor may destroy or archive the paper originals. The parties hereto (i) waive any right to insist or require that Investor produce paper originals, (ii) agree that such images shall be accorded the same force and effect as the paper originals, (iii) agree that Investor is entitled to use such images in lieu of destroyed or archived originals for any purpose, including as admissible evidence in any demand, presentment or other proceedings, and (iv) further agree that any executed facsimile (faxed), scanned, emailed, or other imaged copy of this Agreement or any other Transaction Document shall be deemed to be of the same force and effect as the original manually executed document.

 

  4  
 

 

7.6. Headings. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this Agreement.

 

7.7. Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform to such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

 

7.8. Entire Agreement. This Agreement, together with the other Transaction Documents, contains the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither Company nor Investor makes any representation, warranty, covenant or undertaking with respect to such matters. For the avoidance of doubt, all prior term sheets or other documents between Company and Investor, or any affiliate thereof, related to the transactions contemplated by the Transaction Documents (collectively, “Prior Agreements”), that may have been entered into between Company and Investor, or any affiliate thereof, are hereby null and void and deemed to be replaced in their entirety by the Transaction Documents. To the extent there is a conflict between any term set forth in any Prior Agreement and the term(s) of the Transaction Documents, the Transaction Documents shall govern.

 

7.9. No Reliance. Company acknowledges and agrees that neither Investor nor any of its officers, directors, members, managers, representatives or agents has made any representations or warranties to Company or any of its officers, directors, representatives, agents or employees except as expressly set forth in the Transaction Documents and, in making its decision to enter into the transactions contemplated by the Transaction Documents, Company is not relying on any representation, warranty, covenant or promise of Investor or its officers, directors, members, managers, agents or representatives other than as set forth in the Transaction Documents.

 

7.10. Amendments. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by both parties hereto.

 

7.11. Notices. Any notice required or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall be deemed effectively given on the earliest of: (i) the date delivered, if delivered by personal delivery as against written receipt therefor or by email to an executive officer, or by facsimile (with successful transmission confirmation), (ii) the earlier of the date delivered or the third business day after deposit, postage prepaid, in the United States Postal Service by certified mail, or (iii) the earlier of the date delivered or the third business day after mailing by express courier, with delivery costs and fees prepaid, in each case, addressed to each of the other parties thereunto entitled at the following addresses (or at such other addresses as such party may designate by five (5) calendar days’ advance written notice similarly given to each of the other parties hereto):

 

If to Company:

 

Cancer Genetics, Inc.

Attn: Jay Roberts, CEO

201 Route 17 North, 2nd Floor

Rutherford, New Jersey 07070

 

  5  
 

 

 

With a copy to (which copy shall not constitute notice):

 

Lowenstein Sandler LLC

Attn: Alan Wovsaniker

One Lowenstein Drive

Roseland, New Jersey 07068

 

If to Investor:

 

Atlas Sciences, LLC

Attn: John Fife

303 East Wacker Drive, Suite 1040

Chicago, Illinois 60601

 

With a copy to (which copy shall not constitute notice):

 

Hansen Black Anderson Ashcraft PLLC

Attn: Jonathan K. Hansen

3051 West Maple Loop Drive, Suite 325

Lehi, Utah 84043

 

7.12. Successors and Assigns. This Agreement or any of the severable rights and obligations inuring to the benefit of or to be performed by Investor hereunder may be assigned by Investor to a third party, including its affiliates, in whole or in part, without the need to obtain Company’s consent thereto. Company may not assign its rights or obligations under this Agreement or delegate its duties hereunder without the prior written consent of Investor.

 

7.13. Survival. The representations and warranties of Company and the agreements and covenants set forth in this Agreement shall survive the Closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of Investor. Company agrees to indemnify and hold harmless Investor and all its officers, directors, employees, attorneys, and agents for loss or damage arising as a result of or related to any breach or alleged breach by Company of any of its representations, warranties and covenants set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

 

7.14. Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

7.15. Investor’s Rights and Remedies Cumulative. All rights, remedies, and powers conferred in this Agreement and the Transaction Documents are cumulative and not exclusive of any other rights or remedies, and shall be in addition to every other right, power, and remedy that Investor may have, whether specifically granted in this Agreement or any other Transaction Document, or existing at law, in equity, or by statute, and any and all such rights and remedies may be exercised from time to time and as often and in such order as Investor may deem expedient.

 

  6  
 

 

7.16. Attorneys’ Fees and Cost of Collection. In the event of any arbitration or action at law or in equity to enforce or interpret the terms of this Agreement or any of the other Transaction Documents, the parties agree that the prevailing party (which, for the avoidance of doubt, shall be determined by the body adjudicating the dispute) shall be entitled to an additional award of the full amount of the reasonable attorneys’ fees, deposition costs, and expenses paid by such prevailing party in connection with arbitration or litigation without reduction or apportionment based upon the individual claims or defenses giving rise to the fees and expenses. Nothing herein shall restrict or impair an arbitrator’s or a court’s power to award fees and expenses for frivolous or bad faith pleading. If (i) the Note is placed in the hands of an attorney for collection or enforcement prior to commencing arbitration or legal proceedings, or is collected or enforced through any arbitration or legal proceeding, or Investor otherwise takes action to collect amounts due under the Note or to enforce the provisions of the Note, or (ii) there occurs any bankruptcy, reorganization, receivership of Company or other proceedings affecting Company’s creditors’ rights and involving a claim under the Note; then Company shall pay the costs incurred by Investor for such collection, enforcement or action or in connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, attorneys’ fees, expenses, deposition costs, and disbursements.

 

7.17. Waiver. No waiver of any provision of this Agreement shall be effective unless it is in the form of a writing signed by the party granting the waiver. No waiver of any provision or consent to any prohibited action shall constitute a waiver of any other provision or consent to any other prohibited action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or commit a party to provide a waiver or consent in the future except to the extent specifically set forth in writing.

 

7.18. Waiver of Jury Trial. EACH PARTY TO THIS AGREEMENT IRREVOCABLY WAIVES ANY AND ALL RIGHTS SUCH PARTY MAY HAVE TO DEMAND THAT ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT, OR THE RELATIONSHIPS OF THE PARTIES HERETO BE TRIED BY JURY. THIS WAIVER EXTENDS TO ANY AND ALL RIGHTS TO DEMAND A TRIAL BY JURY ARISING UNDER COMMON LAW OR ANY APPLICABLE STATUTE, LAW, RULE OR REGULATION. FURTHER, EACH PARTY HERETO ACKNOWLEDGES THAT SUCH PARTY IS KNOWINGLY AND VOLUNTARILY WAIVING SUCH PARTY’S RIGHT TO DEMAND TRIAL BY JURY.

 

7.19. Time is of the Essence. Time is expressly made of the essence with respect to each and every provision of this Agreement and the other Transaction Documents.

 

7.20. Voluntary Agreement. Company has carefully read this Agreement and each of the other Transaction Documents and has asked any questions needed for Company to understand the terms, consequences and binding effect of this Agreement and each of the other Transaction Documents and fully understand them. Company has had the opportunity to seek the advice of an attorney of Company’s choosing, or has waived the right to do so, and is executing this Agreement and each of the other Transaction Documents voluntarily and without any duress or undue influence by Investor or anyone else.

 

[Remainder of page intentionally left blank; signature page follows]

 

  7  
 

 

IN WITNESS WHEREOF, the undersigned Investor and Company have caused this Agreement to be duly executed as of the date first above written.

 

SUBSCRIPTION AMOUNT:  
   
Principal Amount of Note: $1,347,500.00
   
Purchase Price: $1,250,000.00

 

  INVESTOR:
     
  Atlas Sciences, LLC
     
  By: Iliad Research and Trading, L.P., its Manager
     
  By: Iliad Management, LLC, its General Partner
     
  By: Fife Trading, Inc., its Manager
     
  By:  
    John M. Fife, President
     
  COMPANY:
     
  Cancer Genetics, Inc.
     
  By:  
  Name:  
  Title:  

 

ATTACHED EXHIBITS:

 

Exhibit A

Note
Exhibit B Flow of Funds
Exhibit C Secretary’s Certificate
Exhibit D Arbitration Provisions

 

[Signature Page to Note Purchase Agreement]

 

     
 

 

Exhibit B

 

FLOW OF FUNDS

 

ORIGINAL PRINCIPAL BALANCE OF THE NOTE: $1,347,500.00
     
LESS:  
     
  ORIGINAL ISSUE DISCOUNT: ($87,500.00)
     
  TRANSACTION EXPENSE: ($10,000.00)
     
PURCHASE PRICE TO COMPANY: $1,250,000.00
     
PURCHASE PRICE TO BE WIRED AS FOLLOWS:  
     
  ILIAD RESEARCH AND TRADING, L.P.: $1,250,000.00
  (TO REPAY PRIOR INDEBTEDNESS OF COMPANY)  
     
  COMPANY: $0.00

 

  ACKNOWLEDGED AND AGREED:
     
  INVESTOR:
     
  Atlas Sciences, LLC
     
  By: Iliad Research and Trading, L.P., its Manager
     
  By: Iliad Management, LLC, its General Partner
     
  By: Fife Trading, Inc., its Manager
     
  By:  
    John M. Fife, President
     
  COMPANY:
     
  Cancer Genetics, Inc.
     
  By:  
  Name:  
  Title:  

 

     
 

 

Exhibit D

 

ARBITRATION PROVISIONS

 

1. 1. Dispute Resolution. For purposes of this Exhibit D, the term “Claims” means any disputes, claims, demands, causes of action, requests for injunctive relief, requests for specific performance, liabilities, damages, losses, or controversies whatsoever arising from, related to, or connected with the transactions contemplated in the Transaction Documents and any communications between the parties related thereto, including without limitation any claims of mutual mistake, mistake, fraud, misrepresentation, failure of formation, failure of consideration, promissory estoppel, unconscionability, failure of condition precedent, rescission, and any statutory claims, tort claims, contract claims, or claims to void, invalidate or terminate the Agreement (or these Arbitration Provisions (defined below)) or any of the other Transaction Documents. For the avoidance of doubt, Investor’s pursuit of an injunction or other Claim pursuant to these Arbitration Provisions (as defined below) or a court will not later prevent Investor under the doctrines of claim preclusion, issue preclusion, res judicata or other similar legal doctrines from pursuing other Claims in the future. The parties to this Agreement (the “parties”) hereby agree that the Claims may be arbitrated in one or more Arbitrations pursuant to these Arbitration Provisions. The parties hereby agree that the arbitration provisions set forth in this Exhibit D (“Arbitration Provisions”) are binding on each of them. As a result, any attempt to rescind the Agreement (or these Arbitration Provisions) or declare the Agreement (or these Arbitration Provisions) or any other Transaction Document invalid or unenforceable for any reason is subject to these Arbitration Provisions. These Arbitration Provisions shall also survive any termination or expiration of the Agreement. Any capitalized term not defined in these Arbitration Provisions shall have the meaning set forth in the Agreement.

 

2. Arbitration. Except as otherwise provided herein, all Claims must be submitted to arbitration (“Arbitration”) to be conducted exclusively in Salt Lake County, Utah and pursuant to the terms set forth in these Arbitration Provisions. Subject to the arbitration appeal right provided for in Paragraph 5 below (the “Appeal Right”), the parties agree that the award of the arbitrator rendered pursuant to Paragraph 4 below (the “Arbitration Award”) shall be (a) final and binding upon the parties, (b) the sole and exclusive remedy between them regarding any Claims, counterclaims, issues, or accountings presented or pleaded to the arbitrator, and (c) promptly payable in United States dollars free of any tax, deduction or offset (with respect to monetary awards). Subject to the Appeal Right, any costs or fees, including without limitation attorneys’ fees, incurred in connection with or incident to enforcing the Arbitration Award shall, to the maximum extent permitted by law, be charged against the party resisting such enforcement. The Arbitration Award shall include default interest (as defined or otherwise provided for in the Note, “Default Interest”) (with respect to monetary awards) at the rate specified in the Note for Default Interest both before and after the Arbitration Award. Judgment upon the Arbitration Award will be entered and enforced by any state or federal court sitting in Salt Lake County, Utah.

 

3. The Arbitration Act. The parties hereby incorporate herein the provisions and procedures set forth in the Utah Uniform Arbitration Act, U.C.A. § 78B-11-101 et seq. (as amended or superseded from time to time, the “Arbitration Act”). Notwithstanding the foregoing, pursuant to, and to the maximum extent permitted by, Section 105 of the Arbitration Act, in the event of conflict or variation between the terms of these Arbitration Provisions and the provisions of the Arbitration Act, the terms of these Arbitration Provisions shall control and the parties hereby waive or otherwise agree to vary the effect of all requirements of the Arbitration Act that may conflict with or vary from these Arbitration Provisions.

 

4. Arbitration Proceedings. Arbitration between the parties will be subject to the following:

 

4.1 Initiation of Arbitration. Pursuant to Section 110 of the Arbitration Act, the parties agree that a party may initiate Arbitration by giving written notice to the other party (“Arbitration Notice”) in the same manner that notice is permitted under Section 7.11 of the Agreement; provided, however, that the Arbitration Notice may not be given by email or fax. Arbitration will be deemed initiated as of the date that the Arbitration Notice is deemed delivered to such other party under Section 7.11 of the Agreement (the “Service Date”). After the Service Date, information may be delivered, and notices may be given, by email or fax pursuant to Section 7.11 of the Agreement or any other method permitted thereunder. The Arbitration Notice must describe the nature of the controversy, the remedies sought, and the election to commence Arbitration proceedings. All Claims in the Arbitration Notice must be pleaded consistent with the Utah Rules of Civil Procedure.

 

     
 

 

4.2 Selection and Payment of Arbitrator.

 

(a) Within ten (10) calendar days after the Service Date, each party shall select and submit to the other the names of five (5) arbitrators that are designated as “neutrals” or qualified arbitrators by Utah ADR Services (http://www.utahadrservices.com) (such five (5) designated persons hereunder are referred to herein as the “Proposed Arbitrators”). For the avoidance of doubt, each Proposed Arbitrator must be qualified as a “neutral” with Utah ADR Services. Within five (5) calendar days after each party has submitted the names of the Proposed Arbitrators, the other party must select, by written notice select one (1) of the Proposed Arbitrators from the other’s list to act as one of the arbitrators for the parties under these Arbitration Provisions. If a party fails to select one of the other party’s Proposed Arbitrators in writing within such 5-day period, then the party providing the list may select the arbitrator from its own Proposed Arbitrators by providing written notice of such selection to the party that has failed to make a selection. If the parties mutually agree, the matter shall be determined by such two arbitrators. If the parties do not so agree, the two arbitrators selected above shall select a third “neutral” within five (5) calendar days from a “neutral” who may but need not be a person who appeared on either parties’ list, or else the Utah ADR Services will be asked to designate a third arbitrator.

 

(b) If a party fails to submit its Proposed Arbitrators within ten (10) calendar days after the Service Date pursuant to subparagraph (a) above, then such party shall be deemed to have waived its right to designate an arbitrator and the dispute shall be decided by the one arbitrator selected pursuant to clause (a) above.

 

(c) If a Proposed Arbitrator chosen to serve as arbitrator declines or is otherwise unable to serve as arbitrator, then the party that selected such Proposed Arbitrator may select one (1) of the other three (3) Proposed Arbitrators within three (3) calendar days of the date the chosen Proposed Arbitrator declines or notifies the parties he or she is unable to serve as arbitrator. If all three (3) Proposed Arbitrators decline or are otherwise unable to serve as arbitrator, then the arbitrator selection process shall begin again in accordance with this Paragraph 4.2.

 

(d) The date that the Proposed Arbitrators selected pursuant to this Paragraph 4.2 agree in writing (including via email) delivered to both parties to serve as the arbitrator hereunder is referred to herein as the “Arbitration Commencement Date”. If an arbitrator resigns or is unable to act during the Arbitration, a replacement arbitrator shall be chosen in accordance with this Paragraph 4.2 to continue the Arbitration. If Utah ADR Services ceases to exist or to provide a list of neutrals and there is no successor thereto, then the arbitrator shall be selected under the then prevailing rules of the American Arbitration Association.

 

(e) Subject to Paragraph 4.10 below, the cost of the arbitrator must be paid equally by both parties. Subject to Paragraph 4.10 below, if one party refuses or fails to pay its portion of the arbitrator fee, then the other party can advance such unpaid amount (subject to the accrual of Default Interest thereupon), with such amount being added to or subtracted from, as applicable, the Arbitration Award.

 

4.3 Applicability of Certain Utah Rules. The parties agree that the Arbitration shall be conducted generally in accordance with the Utah Rules of Civil Procedure and the Utah Rules of Evidence. More specifically, the Utah Rules of Civil Procedure shall apply, without limitation, to the filing of any pleadings, motions or memoranda, the conducting of discovery, and the taking of any depositions. The Utah Rules of Evidence shall apply to any hearings, whether telephonic or in person, held by the arbitrator. Notwithstanding the foregoing, it is the parties’ intent that the incorporation of such rules will in no event supersede these Arbitration Provisions. In the event of any conflict between the Utah Rules of Civil Procedure or the Utah Rules of Evidence and these Arbitration Provisions, these Arbitration Provisions shall control.

 

4.4 Answer and Default. An answer and any counterclaims to the Arbitration Notice shall be required to be delivered to the party initiating the Arbitration within twenty (20) calendar days after the Arbitration Commencement Date. If an answer is not delivered by the required deadline, the arbitrator must provide written notice to the defaulting party stating that the arbitrator will enter a default award against such party if such party does not file an answer within five (5) calendar days of receipt of such notice. If an answer is not filed within the five (5) day extension period, the arbitrator must render a default award, consistent with the relief requested in the Arbitration Notice, against a party that fails to submit an answer within such time period.

 

Arbitration Provisions, Page 2
 

 

4.5 Related Litigation. The party that delivers the Arbitration Notice to the other party shall have the option to also commence concurrent legal proceedings with any state or federal court sitting in Salt Lake County, Utah (“Litigation Proceedings”), subject to the following: (a) the complaint in the Litigation Proceedings is to be substantially similar to the claims set forth in the Arbitration Notice, provided that an additional cause of action to compel arbitration will also be included therein, (b) so long as the other party files an answer to the complaint in the Litigation Proceedings and an answer to the Arbitration Notice, the Litigation Proceedings will be stayed pending an Arbitration Award (or Appeal Panel Award (defined below), as applicable) hereunder, (c) if the other party fails to file an answer in the Litigation Proceedings or an answer in the Arbitration proceedings, then the party initiating Arbitration shall be entitled to a default judgment consistent with the relief requested, to be entered in the Litigation Proceedings, and (d) any legal or procedural issue arising under the Arbitration Act that requires a decision of a court of competent jurisdiction may be determined in the Litigation Proceedings. Any award of the arbitrator (or of the Appeal Panel (defined below)) may be entered in such Litigation Proceedings pursuant to the Arbitration Act.

 

4.6 Discovery. Pursuant to Section 118(8) of the Arbitration Act, the parties agree that discovery shall be conducted as follows:

 

(a) Written discovery will only be allowed if the likely benefits of the proposed written discovery outweigh the burden or expense thereof, and the written discovery sought is likely to reveal information that will satisfy a specific element of a claim or defense already pleaded in the Arbitration. The party seeking written discovery shall always have the burden of showing that all of the standards and limitations set forth in these Arbitration Provisions are satisfied. The scope of discovery in the Arbitration proceedings shall also be limited as follows:

 

(i) To facts directly connected with the transactions contemplated by the Agreement.

 

(ii) To facts and information that cannot be obtained from another source or in another manner that is more convenient, less burdensome or less expensive than in the manner requested.

 

(b) No party shall be allowed (i) more than fifteen (15) interrogatories (including discrete subparts), (ii) more than fifteen (15) requests for admission (including discrete subparts), (iii) more than ten (10) document requests (including discrete subparts), or (iv) more than three (3) depositions (excluding expert depositions) for a maximum of seven (7) hours per deposition. The costs associated with depositions will be borne by the party taking the deposition. The party defending the deposition will submit a notice to the party taking the deposition of the estimated attorneys’ fees that such party expects to incur in connection with defending the deposition. If the party defending the deposition fails to submit an estimate of attorneys’ fees within five (5) calendar days of its receipt of a deposition notice, then such party shall be deemed to have waived its right to the estimated attorneys’ fees. The party taking the deposition must pay the party defending the deposition the estimated attorneys’ fees prior to taking the deposition, unless such obligation is deemed to be waived as set forth in the immediately preceding sentence. If the party taking the deposition believes that the estimated attorneys’ fees are unreasonable, such party may submit the issue to the arbitrator for a decision. All depositions requested by the Company will be taken in Utah, and all depositions requested by the Investor will be taken in New Jersey.

 

(c) All discovery requests (including document production requests included in deposition notices) must be submitted in writing to the arbitrator and the other party. The party submitting the written discovery requests must include with such discovery requests a detailed explanation of how the proposed discovery requests satisfy the requirements of these Arbitration Provisions and the Utah Rules of Civil Procedure. The receiving party will then be allowed, within five (5) calendar days of receiving the proposed discovery requests, to submit to the arbitrator an estimate of the attorneys’ fees and costs associated with responding to such written discovery requests and a written challenge to each applicable discovery request. After receipt of an estimate of attorneys’ fees and costs and/or challenge(s) to one or more discovery requests, consistent with subparagraph (c) above, the arbitrator will within three (3) calendar days make a finding as to the likely attorneys’ fees and costs associated with responding to the discovery requests and issue an order that (i) requires the requesting party to prepay the attorneys’ fees and costs associated with responding to the discovery requests, and (ii) requires the responding party to respond to the discovery requests as limited by the arbitrator within twenty-five (25) calendar days of the arbitrator’s finding with respect to such discovery requests. If a party entitled to submit an estimate of attorneys’ fees and costs and/or a challenge to discovery requests fails to do so within such 5-day period, the arbitrator will make a finding that (A) there are no attorneys’ fees or costs associated with responding to such discovery requests, and (B) the responding party must respond to such discovery requests (as may be limited by the arbitrator) within twenty-five (25) calendar days of the arbitrator’s finding with respect to such discovery requests. Any party submitting any written discovery requests, including without limitation interrogatories, requests for production subpoenas to a party or a third party, or requests for admissions, must prepay the estimated attorneys’ fees and costs, before the responding party has any obligation to produce or respond to the same, unless such obligation is deemed waived as set forth above.

 

Arbitration Provisions, Page 3
 

 

(d) In order to allow a written discovery request, the arbitrator must find that the discovery request satisfies the standards set forth in these Arbitration Provisions and the Utah Rules of Civil Procedure. The arbitrator must strictly enforce these standards. If a discovery request does not satisfy any of the standards set forth in these Arbitration Provisions or the Utah Rules of Civil Procedure, the arbitrator may modify such discovery request to satisfy the applicable standards, or strike such discovery request in whole or in part.

 

(e) Each party may submit expert reports (and rebuttals thereto), provided that such reports must be submitted within sixty (60) days of the Arbitration Commencement Date. Each party will be allowed a maximum of two (2) experts. Expert reports must contain the following: (i) a complete statement of all opinions the expert will offer at trial and the basis and reasons for them; (ii) the expert’s name and qualifications, including a list of all the expert’s publications within the preceding ten (10) years, and a list of any other cases in which the expert has testified at trial or in a deposition or prepared a report within the preceding ten (10) years; and (iii) the compensation to be paid for the expert’s report and testimony. The parties are entitled to depose any other party’s expert witness one (1) time for no more than seven (7) hours. An expert may not testify in a party’s case-in-chief concerning any matter not fairly disclosed in the expert report.

 

4.6 Dispositive Motions. Each party shall have the right to submit dispositive motions pursuant Rule 12 or Rule 56 of the Utah Rules of Civil Procedure (a “Dispositive Motion”). The party submitting the Dispositive Motion may, but is not required to, deliver to the arbitrator and to the other party a memorandum in support (the “Memorandum in Support”) of the Dispositive Motion. Within seven (7) calendar days of delivery of the Memorandum in Support, the other party shall deliver to the arbitrator and to the other party a memorandum in opposition to the Memorandum in Support (the “Memorandum in Opposition”). Within seven (7) calendar days of delivery of the Memorandum in Opposition, as applicable, the party that submitted the Memorandum in Support shall deliver to the arbitrator and to the other party a reply memorandum to the Memorandum in Opposition (“Reply Memorandum”). If the applicable party shall fail to deliver the Memorandum in Opposition as required above, or if the other party fails to deliver the Reply Memorandum as required above, then the applicable party shall lose its right to so deliver the same, and the Dispositive Motion shall proceed regardless.

 

4.7 Confidentiality. All information disclosed by either party (or such party’s agents) during the Arbitration process (including without limitation information disclosed during the discovery process or any Appeal (defined below)) shall be considered confidential in nature. Each party agrees not to disclose any confidential information received from the other party (or its agents) during the Arbitration process (including without limitation during the discovery process or any Appeal) unless (a) prior to or after the time of disclosure such information becomes public knowledge or part of the public domain, not as a result of any inaction or action of the receiving party or its agents, (b) such information is required by a court order, subpoena or similar legal duress to be disclosed if such receiving party has notified the other party thereof in writing and given it a reasonable opportunity to obtain a protective order from a court of competent jurisdiction prior to disclosure, or (c) such information is disclosed to the receiving party’s agents, representatives and legal counsel on a need to know basis who each agree in writing not to disclose such information to any third party. Pursuant to Section 118(5) of the Arbitration Act, the arbitrator is hereby authorized and directed to issue a protective order to prevent the disclosure of privileged information and confidential information upon the written request of either party.

 

4.8 Authorization; Timing; Scheduling Order. Subject to all other portions of these Arbitration Provisions, the parties hereby authorize and direct the arbitrator to take such actions and make such rulings as may be necessary to carry out the parties’ intent for the Arbitration proceedings to be efficient and expeditious. Pursuant to Section 120 of the Arbitration Act, the parties hereby agree that an Arbitration Award must be made within one hundred twenty (120) calendar days after the Arbitration Commencement Date. The arbitrator is hereby authorized and directed to hold a scheduling conference within ten (10) calendar days after the Arbitration Commencement Date in order to establish a scheduling order with various binding deadlines for discovery, expert testimony, and the submission of documents by the parties to enable the arbitrator to render a decision prior to the end of such 120-day period.

 

Arbitration Provisions, Page 4
 

 

4.9 Relief. The arbitrator shall have the right to award or include in the Arbitration Award (or in a preliminary ruling) any relief which the arbitrator deems proper under the circumstances, including, without limitation, specific performance and injunctive relief, provided that the arbitrator may not award exemplary or punitive damages.

 

4.10 Fees and Costs. As part of the Arbitration Award, the arbitrator is hereby directed to require the losing party to reimburse the prevailing party for all reasonable attorneys’ fees, arbitrator costs and fees, deposition costs, other discovery costs, and other expenses, costs or fees paid or otherwise incurred by the prevailing party in connection with the Arbitration. For the avoidance of doubt, the arbitrator must choose one party as the prevailing party.

 

5. Arbitration Appeal.

 

5.1 Initiation of Appeal. Following the entry of the Arbitration Award, either party (the “Appellant”) shall have a period of thirty (30) calendar days in which to notify the other party (the “Appellee”), in writing, that the Appellant elects to appeal (the “Appeal”) the Arbitration Award (such notice, an “Appeal Notice”) to a panel of arbitrators as provided in Paragraph 5.2 below. The date the Appellant delivers an Appeal Notice to the Appellee is referred to herein as the “Appeal Date”. The Appeal Notice must be delivered to the Appellee in accordance with the provisions of Paragraph 4.1 above with respect to delivery of an Arbitration Notice. In addition, together with delivery of the Appeal Notice to the Appellee, the Appellant must also pay for (and provide proof of such payment to the Appellee together with delivery of the Appeal Notice) a bond in the amount of 110% of the sum the Appellant owes to the Appellee as a result of the Arbitration Award the Appellant is appealing. In the event an Appellant delivers an Appeal Notice to the Appellee (together with proof of payment of the applicable bond) in compliance with the provisions of this Paragraph 5.1, the Appeal will occur as a matter of right and, except as specifically set forth herein, will not be further conditioned. In the event a party does not deliver an Appeal Notice (along with proof of payment of the applicable bond) to the other party within the deadline prescribed in this Paragraph 5.1, such party shall lose its right to appeal the Arbitration Award. If no party delivers an Appeal Notice (along with proof of payment of the applicable bond) to the other party within the deadline described in this Paragraph 5.1, the Arbitration Award shall be final. The parties acknowledge and agree that any Appeal shall be deemed part of the parties’ agreement to arbitrate for purposes of these Arbitration Provisions and the Arbitration Act.

 

5.2 Selection and Payment of Appeal Panel. In the event an Appellant delivers an Appeal Notice to the Appellee (together with proof of payment of the applicable bond) in compliance with the provisions of Paragraph 5.1 above, the Appeal will be heard by a three (3) person arbitration panel (the “Appeal Panel”).

 

(a) Within ten (10) calendar days after the Appeal Date, each party shall select and submit to the other the names of five (5) arbitrators that are designated as “neutrals” or qualified arbitrators by Utah ADR Services (http://www.utahadrservices.com) (such five (5) designated persons hereunder are referred to herein as the “Proposed Appeal Arbitrators”). For the avoidance of doubt, each Proposed Appeal Arbitrator must be qualified as a “neutral” with Utah ADR Services, and shall not be the arbitrator who rendered the Arbitration Award being appealed (the “Original Arbitrator”). Within five (5) calendar days after each party has submitted to the Appellant the names of the Proposed Appeal Arbitrators, the other party must select, by written notice to the Appellee, one (1) of the other party’s Proposed Appeal Arbitrators to act as a member of the Appeal Panel. If a party fails to select a Proposed Appeal Arbitrators in writing within such 5-day period, then the party providing the list may select the arbitrator from its own Proposed Arbitrators by providing written notice of such selection to the party that has failed to make a selection. The two Appeal Arbitrators selected above shall select a third “neutral” within five (5) calendar days from a “neutral” who may but need not be a person who appeared on either parties’ list, or else the Utah ADR Services will be asked to designate a third Appeal Arbitrator.

 

(b) If a party fails to submit its Proposed Appeal Arbitrators within ten (10) calendar days after the Service Date pursuant to subparagraph (a) above, then such party shall be deemed to have waived its right to designate an Appeals Arbitrator and the appeal shall be decided by the two Appeals Arbitrators selected pursuant to clause (a) above, plus one additional neutral Appeals Arbitrator selected by them.

 

Arbitration Provisions, Page 5
 

 

(c) If a selected Proposed Appeal Arbitrator declines or is otherwise unable to serve, then the party that selected such Proposed Appeal Arbitrator may select one (1) of the other five (5) designated Proposed Appeal Arbitrators within three (3) calendar days of the date a chosen Proposed Appeal Arbitrator declines or notifies the parties he or she is unable to serve as an arbitrator. If at least three (3) of the five (5) designated Proposed Appeal Arbitrators decline or are otherwise unable to serve, then the Proposed Appeal Arbitrator selection process shall begin again in accordance with this Paragraph 5.2; provided, however, that any Proposed Appeal Arbitrators who have already agreed to serve shall remain on the Appeal Panel.

 

(d) The date that all three (3) Proposed Appeal Arbitrators selected pursuant to this Paragraph 5.2 agree in writing (including via email) delivered to both the Appellant and the Appellee to serve as members of the Appeal Panel hereunder is referred to herein as the “Appeal Commencement Date”. No later than five (5) calendar days after the Appeal Commencement Date, the Appellee shall designate in writing (including via email) to the Appellant and the Appeal Panel the name of one (1) of the three (3) members of the Appeal Panel to serve as the lead arbitrator in the Appeal proceedings. Each member of the Appeal Panel shall be deemed an arbitrator for purposes of these Arbitration Provisions and the Arbitration Act, provided that, in conducting the Appeal, the Appeal Panel may only act or make determinations upon the approval or vote of no less than the majority vote of its members, as announced or communicated by the lead arbitrator on the Appeal Panel. If an arbitrator on the Appeal Panel ceases or is unable to act during the Appeal proceedings, a replacement arbitrator shall be chosen in accordance with Paragraph 5.2 above to continue the Appeal as a member of the Appeal Panel. If Utah ADR Services ceases to exist or to provide a list of neutrals, then the arbitrators for the Appeal Panel shall be selected under the then prevailing rules of the American Arbitration Association.

 

(d) Subject to Paragraph 5.7 below, the cost of the Appeal Panel must be paid entirely by the Appellant.

 

5.3 Appeal Procedure. The Appeal will be deemed an appeal of the entire Arbitration Award. In conducting the Appeal, the Appeal Panel shall conduct a de novo review of all Claims described or otherwise set forth in the Arbitration Notice. Subject to the foregoing and all other provisions of this Paragraph 5, the Appeal Panel shall conduct the Appeal in a manner the Appeal Panel considers appropriate for a fair and expeditious disposition of the Appeal, may hold one or more hearings and permit oral argument, and may review all previous evidence and discovery, together with all briefs, pleadings and other documents filed with the Original Arbitrator (as well as any documents filed with the Appeal Panel pursuant to Paragraph 5.4(a) below). Notwithstanding the foregoing, in connection with the Appeal, the Appeal Panel shall not permit the parties to conduct any additional discovery or raise any new Claims to be arbitrated, shall not permit new witnesses or affidavits, and shall not base any of its findings or determinations on the Original Arbitrator’s findings or the Arbitration Award.

 

5.4 Timing.

 

(a) Within seven (7) calendar days of the Appeal Commencement Date, the Appellant (i) shall deliver or cause to be delivered to the Appeal Panel copies of the Appeal Notice, all discovery conducted in connection with the Arbitration, and all briefs, pleadings and other documents filed with the Original Arbitrator (which material Appellee shall have the right to review and supplement if necessary), and (ii) may, but is not required to, deliver to the Appeal Panel and to the Appellee a Memorandum in Support of the Appellant’s arguments concerning or position with respect to all Claims, counterclaims, issues, or accountings presented or pleaded in the Arbitration. Within seven (7) calendar days of the Appellant’s delivery of the Memorandum in Support, as applicable, the Appellee shall deliver to the Appeal Panel and to the Appellant a Memorandum in Opposition to the Memorandum in Support. Within seven (7) calendar days of the Appellee’s delivery of the Memorandum in Opposition, as applicable, the Appellant shall deliver to the Appeal Panel and to the Appellee a Reply Memorandum to the Memorandum in Opposition. If the Appellant shall fail to substantially comply with the requirements of clause (i) of this subparagraph (a), the Appellant shall lose its right to appeal the Arbitration Award, and the Arbitration Award shall be final. If the Appellee shall fail to deliver the Memorandum in Opposition as required above, or if the Appellant shall fail to deliver the Reply Memorandum as required above, then the Appellee or the Appellant, as the case may be, shall lose its right to so deliver the same, and the Appeal shall proceed regardless.

 

(b) Subject to subparagraph (a) above, the parties hereby agree that the Appeal must be heard by the Appeal Panel within thirty (30) calendar days of the Appeal Commencement Date, and that the Appeal Panel must render its decision within thirty (30) calendar days after the Appeal is heard (and in no event later than sixty (60) calendar days after the Appeal Commencement Date).

 

Arbitration Provisions, Page 6
 

 

5.5 Appeal Panel Award. The Appeal Panel shall issue its decision (the “Appeal Panel Award”) through the lead arbitrator on the Appeal Panel. Notwithstanding any other provision contained herein, the Appeal Panel Award shall (a) supersede in its entirety and make of no further force or effect the Arbitration Award (provided that any protective orders issued by the Original Arbitrator shall remain in full force and effect), (b) be final and binding upon the parties, with no further rights of appeal, (c) be the sole and exclusive remedy between the parties regarding any Claims, counterclaims, issues, or accountings presented or pleaded in the Arbitration, and (d) be promptly payable in United States dollars free of any tax, deduction or offset (with respect to monetary awards). Any costs or fees, including without limitation attorneys’ fees, incurred in connection with or incident to enforcing the Appeal Panel Award shall, to the maximum extent permitted by law, be charged against the party resisting such enforcement. The Appeal Panel Award shall include Default Interest (with respect to monetary awards) at the rate specified in the Note for Default Interest both before and after the Arbitration Award. Judgment upon the Appeal Panel Award will be entered and enforced by a state or federal court sitting in Salt Lake County, Utah.

 

5.6 Relief. The Appeal Panel shall have the right to award or include in the Appeal Panel Award any relief which the Appeal Panel deems proper under the circumstances, including, without limitation, specific performance and injunctive relief, provided that the Appeal Panel may not award exemplary or punitive damages.

 

5.7 Fees and Costs. As part of the Appeal Panel Award, the Appeal Panel is hereby directed to require the losing party reimburse the prevailing party the reasonable attorneys’ fees, arbitrator and Appeal Panel costs and fees, deposition costs, other discovery costs, and other expenses, costs or fees paid or otherwise incurred by the prevailing party in connection with the Arbitration (including without limitation in connection with the Appeal). For the avoidance of doubt, the Appeal Panel must choose one party as the prevailing party.

 

6. Miscellaneous.

 

6.1 Severability. If any part of these Arbitration Provisions is found to violate or be illegal under applicable law, then such provision shall be modified to the minimum extent necessary to make such provision enforceable under applicable law, and the remainder of the Arbitration Provisions shall remain unaffected and in full force and effect.

 

6.2 Governing Law. These Arbitration Provisions shall be governed by the laws of the State of Utah without regard to the conflict of laws principles therein.

 

6.3 Interpretation. The headings of these Arbitration Provisions are for convenience of reference only and shall not form part of, or affect the interpretation of, these Arbitration Provisions.

 

6.4 Waiver. No waiver of any provision of these Arbitration Provisions shall be effective unless it is in the form of a writing signed by the party granting the waiver.

 

6.5 Time is of the Essence. Time is expressly made of the essence with respect to each and every provision of these Arbitration Provisions.

 

[Remainder of page intentionally left blank]

 

Arbitration Provisions, Page 7
 

 

 

Execution Document

 

SETTLEMENT AGREEMENT

 

This Settlement Agreement (this “Agreement”) is entered into as of October 21, 2019 by and between NovellusDx Ltd., a company formed under the laws of the State of Israel (“Lender”), and Cancer Genetics, Inc., a Delaware corporation (“Borrower”).

 

RECITALS

 

A.  Borrower and Lender are parties to that certain Credit Agreement dated as of September 18, 2018 (the “Credit Agreement”) and Promissory Note dated the same date (the “Note”). There is due under the Note the principal sum of $1,500,000, plus interest accrued thereon (the amount currently due referred to as the “Outstanding Balance”). Borrower and Lender also entered into an Agreement and Plan of Merger dated September 18, 2018, which was previously terminated (the “Merger Agreement”), and a Registration Rights Agreement. The Credit Agreement (as amended hereby), the Note (as amended hereby), the Merger Agreement, the Registration Rights Agreement and all other documents and agreements entered into in connection therewith or related thereto (other than, for the elimination of doubt, this Agreement), are referred to as the “Transaction Documents”.

 

B.  On July 15, 2019, Borrower entered into a secured creditor asset purchase agreement (the “BioPharma Agreement”) with Partners for Growth IV, L.P., Interpace Diagnostics Group, Inc. (“IDXG”) and a newly-formed subsidiary of IDXG, Interpace BioPharma, Inc. (“Buyer”). Pursuant to the BioPharma Agreement, Buyer issued to the Borrower a promissory note in the initial principal sum of $7,692,300, subject to certain reductions as described in the Borrower’s filings with the SEC (the “Excess Consideration Note”). The Excess Consideration Note will mature on the earlier of the date (i) five (5) business days after the consummation of an investment by Ampersand Capital Partners or any of its affiliates into IDXG or Buyer, following IDXG receiving the approval of its shareholders of the issuance of shares of its common stock in connection therewith and (ii) July 15, 2022.

 

C.  As a result of the transactions described in B above, Borrower and Lender believe they will be able to, and have agreed to settle all claims between them and terminate the Credit Agreement and Note as set forth in this Agreement, and exchange mutual releases subject to the terms, conditions and understandings set forth herein.

 

D.  Capitalized terms used herein but not defined herein shall have the respective meanings ascribed thereto in the Credit Agreement.

 

AGREEMENT

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound hereby, agree as follows:

 

1.  Initial Payment. On the date hereof, Borrower is paying to Lender $100,000 against the principal balance of the Note by wire transfer to an account designated in writing by Lender on or prior to the date hereof.

 

 
 

 

2.  Standstill. For a period beginning as of the date hereof and ending on February 28, 2020 (the “Standstill Period”), Lender will not demand payment of any portion of the Note in cash (the “Standstill”). Notwithstanding the foregoing, the Standstill shall immediately and automatically terminate five (5) business days after Borrower receives one or more payments aggregating at least $5.0 million with respect to the Excess Consideration Note if the payment required under Section 3(a) below has not yet been made.

 

3.  Future Payments. In exchange for the discharge and forgiveness of all amounts due under the Credit Agreement and the Note, and the releases contemplated hereunder, Borrower agrees to make the following payments to Lender:

 

  a) On the fifth (5th) business day after Borrower’s receipt of one or more payments aggregating at least five million dollars ($5,000,000) from Buyer on Buyer’s obligations under the Excess Consideration Note, (such 5th day, the “One Million Payment Date”), Borrower shall pay Lender the sum of one million dollars ($1,000,000) (the “One Million Payment”) in cash by wire transfer of immediately available funds to an account designated in writing by Lender.
     
  b) On the One Million Payment Date and payment by Borrower and receipt by Lender of the One Million Payment, the Credit Agreement and the Note will be deemed modified as set forth herein and as provided in Exhibit A annexed hereto such that, in lieu of all obligations currently and then existing under the Credit Agreement and the Note, Borrower’s sole obligation shall be that commencing one month after the One Million Payment Date and receipt by Lender of the One Million Payment from the Borrower, on each of the first nine monthly anniversaries of the One Million Payment Date, Borrower shall pay Lender the sum of Fifty Thousand Dollars ($50,000) (or an aggregate of Four Hundred Fifty Thousand Dollars ($450,000) to be paid pursuant to this clause (b) and under the Credit Agreement and Note as modified hereunder), in each case in cash by wire transfer of immediately available funds to an account designated in writing by Lender.

 

4.  Amendment and Cancellation of Credit Agreement and Note.

 

  (a) The parties agree that immediately upon the payment by Borrower of the One Million Payment, the Credit Agreement and Note shall be amended effective immediately upon such payment with no further action by the parties being required (i) so that the total amount due thereunder shall at such time be reduced to $450,000, and (ii) as set forth in Exhibit A.
     
  (b) The parties agree that immediately upon the final payment by Borrower pursuant to Section 3(b) above, the Credit Agreement and Note shall be terminated, and all of Borrower’s obligations thereunder shall be deemed discharged and forgiven. Lender shall physically deliver the original Note to the Borrower marked “Cancelled” promptly following its receipt of the last such payment; provided that the failure of Lender to physically deliver such original Note shall not affect the termination and discharge of the Credit Agreement and Note as provided herein, nor the effectiveness of the releases contained in Section 5 below, nor shall such failure modify, amend, waive or otherwise affect any of Borrower’s obligations hereunder.

 

-2-
 

 

5.  General Releases.

 

(a)  Lender’s Release of Borrower. On the One Million Payment Date, upon Borrower making the One Million Payment, Lender, on behalf of itself, its predecessors, successors, affiliates, principals and assigns, (collectively, the “Lender Releasing Parties”), shall be deemed to have fully and irrevocably released and discharged Borrower together with its predecessors, successors, affiliates, and assigns, its direct and indirect subsidiary companies and companies under common control with any of the foregoing, and its past, present, and future officers, directors, managers, shareholders, interest holders, attorneys, agents, employees, representatives, and any person acting by, through, under, or in concert with them (collectively, the “Borrower Released Parties”) from any and all claims, rights, demands, actions, suits, causes of action, grievances, liabilities, obligations, controversies, damages, costs, expenses, losses, and debts, of any nature whatsoever, known or unknown, contingent or definitive, direct or indirect, conditional or unconditional, that the Lender Releasing Parties had, have, or may have against the Borrower Released Parties, including but not limited to claims in respect of any breach or alleged breach by Borrower under the Credit Agreement, the Note, the Registration Rights Agreement, the Merger Agreement or the other Transaction Documents, in each case occurring prior to the date hereof, (the “Lender Released Claims”). The Lender Released Claims include those of which the Lender Releasing Parties are presently unaware or which the Lender Releasing Parties do not presently expect to exist and which, if known to the Lender Releasing Parties, would materially affect their release of the Borrower Released Parties.

 

(b)  Borrower’s Release of Lender. On the One Million Payment Date, upon Borrower making the One Million Payment, Borrower, on behalf of itself, its predecessors, successors, affiliates, principals and assigns (collectively, the “Borrower Releasing Parties”), shall be deemed to have fully and irrevocably released and discharged Lender, together with its predecessors, successors, affiliates, and assigns, its direct and indirect subsidiary companies and companies under common control with any of the foregoing, and its past, present, and future officers, directors, managers, shareholders, interest holders, attorneys, agents, employees, representatives, and any person acting by, through, under, or in concert with them (collectively, the “Lender Released Parties”) from any and all claims, rights, demands, actions, suits, causes of action, grievances, liabilities, obligations, controversies, damages, costs, expenses, losses, and debts, of any nature whatsoever, known or unknown, contingent or definitive, direct or indirect, conditional or unconditional, that the Borrower Releasing Parties had, have, or may have against the Lender Released Parties, including but not limited to claims in respect of any breach or alleged breach by Lender under the Credit Agreement, the Note, the Registration Rights Agreement, the Merger Agreement or the other Transaction Documents, in each case occurring prior to the date hereof (the “Borrower Released Claims”). The Borrower Released Claims include those of which the Borrower Releasing Parties are presently unaware or which the Borrower Releasing Parties do not presently expect to exist and which, if known to the Borrower Releasing Parties, would materially affect their release of the Lender Released Parties.

 

-3-
 

 

(c)  No Release of Claims Relating to this Agreement. Notwithstanding anything in this Agreement to the contrary, the releases set forth in Sections 5(a) and 5(b) above shall not apply to Borrower’s obligation to make the payments aggregating $450,000 required under Section 3(b) hereof and the amended Credit Agreement and Note or any of the Parties’ other obligations under this Agreement.

 

(d)  Reaffirmation Document. Immediately following Lender’s receipt of the final payment contemplated by Section 3(b) hereof and under the amended Credit Agreement and Note, Borrower and Lender shall exchange a form of mutual release reaffirming the releases contemplated by this Section 5 as of the One Million Payment Date, but without the exceptions set forth in Section 5(c).

 

6.  Optional Conversion Upon Payment Default.

 

(a)  In connection with the amendments to the Credit Agreement and Note effected hereby, if Borrower fails to make any payment against the $450,000 balance required pursuant to Section 3(b) hereof and the amended Credit Agreement and Note, within five (5) business days of any payment due date, then, at any time thereafter if the amount is still unpaid, Lender may deliver to Borrower written notice of Lender’s election to convert (the “Conversion Notice”) all, but not less than all, of the amounts then owing and unpaid pursuant the amended Credit Agreement and Note into a number of shares (“Conversion Shares”) of Borrower’s Common Stock, equal to the aggregate amount due and unpaid thereunder divided by $ 0.15 (15 cents). The date on which Lender delivers a Conversion Notice to Borrower is the “Conversion Date”. The Conversion Notice shall be in the form reasonably acceptable to Borrower and shall also attach a reaffirmation of the representations set forth in Section 7.

 

(b)  Lender agrees that any issuance to it of Conversion Shares shall be made in compliance with all applicable rules of Nasdaq, and that it shall sell any Conversion Shares only in accordance with all applicable federal and state securities laws.

 

(c)  Lender and Borrower agree that for the purposes of Rule 144 (“Rule 144”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the holding period of the Note and any Conversion Shares commenced on September 18, 2018, which date is the date that the Note was originally issued to, and paid for by, Lender. Borrower agrees not to take a position contrary to this Section 6(c) in any document, statement, setting, or situation. Borrower agrees to take all action necessary to issue the Conversion Shares without restriction, and not containing any restrictive legend without the need for any action by Lender; and Borrower shall cause its counsel to promptly provide any opinion required by Borrower’s transfer agent such that the transfer agent may issue the Conversion Shares to Lender without restriction, restrictive legends or stop orders. Additionally, Borrower shall instruct its transfer agent that it may accept such an opinion from counsel to Lender, which opinion shall not be subject to Borrower’s review, consent or approval. In furtherance thereof, counsel to Lender may, in its sole discretion, provide an opinion that: (a) the Conversion Shares may be resold pursuant to Rule 144 without volume or manner-of-sale restrictions or current public information requirements; and (b) the transactions contemplated hereby and all other documents associated with this transaction comport with the requirements of Section 3(a)(9) of the Securities Act. Borrower represents that it is not subject to Rule 144(i). Lender agrees to provide counsel with a customary Rule 144 representation letter in connection with a request that it issue any opinion hereunder. The Conversion Shares if issued in accordance with the terms hereof and the amended Credit Agreement and Note will be issued in substitution of and exchange for and not in satisfaction of the Note. Neither the Note as amended hereby nor the Conversion Shares will constitute a novation or satisfaction and accord of the Note.

 

-4-
 

 

(d)  Borrower represents and warrants to Lender that the Conversion Shares have been duly authorized and, if and when issued to Lender in accordance with the terms hereof, shall be validly issued, fully paid and nonassessable. Borrower shall use reasonable efforts to satisfy the current public information requirement under Rule 144(c) until the earlier of (i) the date on which Borrower has paid to Lender all amounts required by Section 3(b) and (ii) the date on which Lender shall have sold all Conversion Shares. Borrower acknowledges and agrees that so long as Lender does not own beneficially more than 9.99% of the issued and outstanding Borrower Common Stock (the “Maximum Percentage”), Lender is not and will not be an “affiliate” of Borrower (as defined under Rule 144). Promptly, and in any event on or prior to the second (2nd) business day immediately following Lender’s delivery of a Conversion Notice and the opinion contemplated by Section (c) above, and provided that at such time Lender does not beneficially own Borrower Common Stock in excess of the Maximum Percentage, Borrower shall cause) its transfer agent to issue such Conversion Shares free and clear of all restrictive legends and stop orders as directed by Lender or its applicable agents. Without the prior written consent of Lender, neither Borrower nor any of its officers, directors, agents or representatives shall provide Lender with any material non-public information regarding Borrower. If, in contravention of the immediately preceding sentence, Borrower provides Lender with any such material non-public information, Borrower shall promptly, and in any event within four (4) business days, publicly disclose such information in any manner compliant with Regulation FD.

 

7.  Representations, Warranties, and Agreements of Lender. As a condition precedent to the issuance of any Conversion Shares, Lender shall represent and warrant to, and covenant and agree with, Borrower as follows, in the Conversion Notice:

 

(a)  Acquisition of Shares Entirely for Own Account. The Conversion Shares are being or will be issued to Lender in reliance upon Lender’s representations to Borrower that the Conversion Shares will be acquired by Lender for investment for Lender’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, other than in compliance with all applicable federal and state securities laws.

 

(b)  Access to Information. Lender has had an opportunity to ask Borrower and its officer’s questions and receive answers regarding Borrower’s business, management, and financial affairs, and the terms and conditions of the purchase of the Conversion Shares.

 

(c)  Restricted Securities. Lender understands that the Conversion Shares have not been, and will not be, registered under the Securities Act. Lender understands that the Conversion Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, Lender must hold the Conversion Shares indefinitely unless the Conversion Shares are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. Lender acknowledges that Borrower has no obligation to register or qualify the Conversion Shares for resale. Lender does not have a short position with respect to any Borrower Common Stock.

 

-5-
 

 

(d)  Accredited Investor. Lender is and will continue to be an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.

 

(e)  Beneficial Ownership. Upon issuance of the Conversion Shares, Lender will beneficially own less than 9.9% of Borrower’s Common Stock.

 

8.  Warranties. Each Party represents and warrants that:

 

(a)  The Party has had the opportunity to consult an attorney with respect to the terms, conditions, and effect of this Agreement;

 

(b)  The Party has fully investigated all the facts and circumstances surrounding the terms of this Agreement and is satisfied that it is fully informed of the terms, conditions, and effect of this Agreement;

 

(c)  The Party is relying on its own judgment in deciding to execute this Agreement and has not been influenced by any statement or representation made by or on behalf of the other Party to this Agreement;

 

(d)  The Party has not assigned or transferred any of the claims, demands, actions, or rights being released by such Party pursuant to this Agreement and covenants not to sue or prosecute, institute or cooperate in the institution, commencement, filing or prosecution of any suit or proceeding in any forum based upon or related to any claim being released herein; and

 

(e)  The Party has full and complete authority to enter into this Agreement, to release the claims such Party will be releasing, and to execute this Agreement. Such Party’s entering into this Agreement and performing its obligations hereunder has been duly authorized by all corporate and other required action on the part of such Party’s board of directors or other applicable governing body, and this Agreement, when duly executed and delivered by such Party, shall be a valid and legally binding obligation of such Party, enforceable against such Party in accordance with its terms.

 

9.  Governing Law; Venue. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware without regard to the principles of conflict of laws of such state that would cause the application of the laws of any other jurisdiction. Each of the parties hereto hereby (a) agrees that any claim, suit, action or other proceeding, directly or indirectly, arising out of, under or relating to this Agreement, will be heard and determined in the Chancery Court of the State of Delaware (and each agrees that no such claim, action, suit or other proceeding relating to this Agreement will be brought by it or any of its Affiliates except in such court), subject to any appeal, provided that if jurisdiction is not then available in the Chancery Court of the State of Delaware, then any such claim, suit, action or other proceeding may be brought in any Delaware state court or any federal court located in the State of Delaware and (b) irrevocably and unconditionally submits to the exclusive jurisdiction of any such court in any such claim, suit, action or other proceeding and irrevocably and unconditionally waives the defense of an inconvenient forum to the maintenance of any such claim, suit, action or other proceeding. Each of the parties hereto further agrees that, to the fullest extent permitted by applicable Law, service of any process, summons, notice or document by U.S. registered mail to such Person’s respective address set forth in Section 15 will be effective service of process for any claim, action, suit or other proceeding in Delaware with respect to any matters to which it has submitted to jurisdiction as set forth above in the immediately preceding sentence. The parties hereto hereby agree that a final judgment in any such claim, suit, action or other proceeding will be conclusive, subject to any appeal, and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by applicable Law.

 

-6-
 

 

10.  Counterparts. This Agreement may be executed in any number of counterparts with the same effect as if all signing parties had signed the same document. All counterparts shall be construed together and constitute the same instrument. The exchange of copies of this Agreement and of signature pages by facsimile transmission or other electronic transmission (including email) shall constitute effective execution and delivery of this Agreement as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile transmission or other electronic transmission (including email) shall be deemed to be their original signatures for all purposes.

 

11.  Severability. If any part of this Agreement is construed to be in violation of any law, such part shall be modified to achieve the objective of the parties to the fullest extent permitted and the balance of this Agreement shall remain in full force and effect.

 

12.  Entire Agreement. This Agreement supersedes all other prior oral or written agreements between Borrower, Lender, its affiliates and persons acting on its behalf with respect to the matters discussed herein, and this Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither Lender nor Borrower makes any representation, warranty, covenant or undertaking with respect to such matters.

 

13.  Amendments. This Agreement may be amended, modified, or supplemented only by written agreement of the parties. No provision of this Agreement may be waived except in writing signed by the party against whom such waiver is sought to be enforced.

 

14.  Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns.

 

-7-
 

 

15.  Notices. Unless otherwise specifically provided for herein, all notices, demands or requests required or permitted under this Agreement to be given to Borrower or Lender shall be given as set forth as follows:

 

If to Borrower:

 

201 Route 17 North, 2nd Floor

Rutherford, NJ 07070, USA

Attention: John A. Roberts, President & CEO

Facsimile: (201) 528-9201

Email: jay.roberts@cgix.com

 

If to Lender:

 

Jerusalem Bio-Park

Hadassah Ein Kerem campus, 1st Kiryat Hadassah

Minrav Building

Jerusalem, Israel, 9112001

Attention: Michael Vidne, CEO

E-mail: michael@novellusdx.bio

 

16.  Further Assurances. Each party shall do and perform or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

[Remainder of page intentionally left blank]

 

-8-
 

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first set forth above.

 

  BORROWER:
     
  CANCER GENETICS, INC.
     
  By: /s/ John A. Roberts
  Name:  John A. Roberts
  Title: Chief Executive Officer
     
  LENDER:
     
  NOVELLUSDX LTD.
     
  By: /s/ Michael Vidne
  Name: Michael Vidne
  Title: Chief Executive Officer

 

-9-
 

 

EXHIBIT A

AMENDMENTS TO CREDIT AGREEMENT AND NOTE

 

The parties agree that, immediately upon Borrower’s payment to Lender of the One Million Payment, the Credit Agreement shall be deemed amended as follows with no further action required by any party:

 

1. Article I is amended to incorporate all definitions in that certain Settlement Agreement, dated October 21, 2019, to which this Exhibit is annexed. All defined terms no longer used in the Credit Agreement or Note, as amended hereby, shall be deemed deleted.

 

The definition of Maturity Date shall be deleted in its entirety, and in its place, it shall read as follows: “Maturity Date” means the date that is nine (9) months after the One Million Payment Date.

 

The definition of Specified Event of Default shall be deleted in its entirety and in its place, it shall read as follows: “Specified Event of Default” shall mean any Event of Default occurring under Section 8.2 (failure to pay when due) and Section 8.6 (bankruptcy), or Section 8.7 (involuntary bankruptcy and non-bankruptcy events).

 

2. Article II – Sections 2.1 shall be deleted in its entirety and in its place, it shall read as follows: “As of the date hereof, the principal amount of the Loan is $450,000 and no other amount is due hereunder. ”

 

3. Section 2.3 shall be deleted in its entirety and in its place, it shall read: “Interest Rate. No interest shall accrue on the Loans due hereunder. All references to interest under the Credit Agreement and Note are hereby deleted.”

 

4. Section 2.5 is hereby amended to provide that notwithstanding anything in the Note or the Lender’s records, the total amount due under the Credit Agreement and on the Note as of the One Million Payment Date is $450,000 in the aggregate, and all other amounts due or which may have been due prior to such date are discharged, waived and/or forgiven.

 

5. Section 2.6 is deleted.

 

6. Section 2.7 is deleted in its entirety, and in its place, it shall read as follows: “Commencing one month after the One Million Payment Date, on each of the first nine monthly anniversaries of the One Million Payment Date, Borrower shall pay Lender the sum of Fifty Thousand Dollars, ($50,000) (or an aggregate of Four Hundred Fifty Thousand Dollars ($450,000)).

 

7. Article IV, Section 5.1 and Article VI are deleted in their entireties.

 

8. Section 7.1 shall be deleted in its entirety and in its place, it shall read: Optional Conversion Upon a Specified Event of Default. If a Specified Event of Default shall have occurred, then, at any time thereafter, Lender may deliver to Borrower written notice of Lender’s election to convert (the “Conversion Notice”) all, but not less than all, of the Loans then outstanding and unpaid (collectively, the “Converted Loan”), into shares of Borrower Common Stock (“Conversion Shares”), in which case the entire aggregate principal amount of the Converted Loan shall convert into a number of Conversion Shares equal to the aggregate principal amount of such Converted Loan, together with all accrued and unpaid interest thereon, divided by $ 0.15 (15 cents). The date on which Lender delivers a Conversion Notice to Borrower is the “Conversion Date”. The Conversion Notice shall specify: (i) the aggregate principal amount of and the aggregate amount of accrued and unpaid interest on the Converted Loan; (ii) the number of Conversion Shares issuable in respect of such Conversion Notice; (iii) the name of the Person to whom the Conversion Shares shall be issued (if other than Lender); and (iv) the physical address or electronic delivery instructions to which Borrower shall deliver such Conversion Shares.

 

-10-
 

 

9. Sections 7.3 and 7.4 are deleted and the method and issuance of the Conversion Shares shall be governed by the terms of the Settlement Agreement.

 

10. Article VIII is amended to delete in its entirety Sections 8.1, 8.3, 8.4, 8.5, 8.8, 8.9, 8.10, 8.11, 8.13 and 8.14.

 

11. Article IX – Section 9.1 is amended to delete the phrase “including without limitation all accrued and unpaid interest”.

 

12. Article X is amended to delete in its entirety paragraphs, 10.2, 10.7 and 10.25.

 

13. Section 10.5 shall be amended to also refer to the Settlement Agreement in addition to the Loan Documents

 

14. Section 10.19 shall be amended such that any defenses provided by the Settlement Agreement are not waived.

 

15. Section 10.23 shall be deleted in its entirety and in its place, it shall read: Inconsistencies. All provisions of the Loan Documents shall be construed as being supplementary and complementary to, and cumulative with, the provisions of the other Loan Documents. However, if there should be an irreconcilable inconsistency between provisions of the Loan Documents, the terms and provisions of the Settlement Agreement shall govern.

 

The parties agree that, immediately upon Borrower’s payment to Lender of the One Million Payment, the Note shall be deemed amended as follows with no further action required by any party:

 

1. The Heading shall be deleted.

 

2. The first 2 paragraphs of the Note shall be deleted and in its place, it shall read:

 

FOR VALUE RECEIVED, the undersigned (the “Borrower”), hereby promises to pay to NovellusDX, Ltd., or its registered assigns (the “Lender”), in accordance with the provisions of the Credit Agreement (as hereinafter defined), the principal amount of $450,000, being the amount due this date under that certain Credit Agreement, dated as of September 14, 2018 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, including pursuant to a Settlement Agreement dated this date, the “Credit Agreement;” the terms defined therein being used herein as therein defined unless otherwise defined herein), by and between the Borrower and the Lender.

 

No interest shall accrue on the Loan. All payments of principal shall be made to the Lender in Dollars in immediately available funds.

 

3. The 4th paragraph of the Note shall be deleted and in its place, it shall read: This Note is the Note referred to in the Credit Agreement and the holder is entitled to the benefits thereof.

 

-11-
 

 

Cancer Genetics, Inc. Announces Strategic Transactions

 

Note Payment Received from Interpace Diagnostics Group, Inc.

 

Settlement Agreement with NovellusDx

 

Restructured Note Agreement with Unsecured Lender

 

M&A Advisory Agreement with H.C. Wainwright & Co.

 

Continuing to significantly reduce its debt burden and
will continue to operate its Discovery Business

 

Rutherford, N.J.— October 24, 2019 – Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in proprietary preclinical test systems supporting drug discovery and development at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers, today announced, among others, the completion of several strategic transactions.

 

As the result of the previously announced sale of the company’s BioPharma business to Interpace Diagnostics Group, Inc. (Nasdaq: IDXG) or its affiliate, IDXG or its affiliate paid approximately $6 million in cash to CGIX on October 24, 2019, as partial settlement of a promissory note in the original face amount of approximately $7.7 million due to CGIX. The gross purchase price of the BioPharma sale transaction was $23.5 million less certain closing adjustments totaling approximately $2.0 million, in addition to the assumption by IDXG of approximately $5.2 million of liabilities relating to the BioPharma business. IDXG or its affiliate paid approximately $9.25 million in cash at closing to the company’s former senior secured lenders, and the balance of the cash portion of the purchase price of approximately $2.25 million (net of expenses) was paid to the company. IDXG’s subsidiary also issued a promissory note to CGIX in the original face amount of approximately $7.7 million, subject to certain post-closing adjustments and holdbacks. The note was due upon the approval by IDXG’s shareholders of a significant investment by Ampersand Capital Partners in IDXG and the closing of that investment, which occurred on October 16, 2019. The payment of approximately $6 million represents amounts known to be due at this date. After known post-closing reductions of approximately $0.8 million, the company may receive up to an additional $0.9 million in January 2020 or thereafter, subject to certain contingencies and set-off rights of IDXG.

 

Previously, CGIX borrowed $1.5 million under a credit agreement and unsecured convertible promissory note with NovellusDx Ltd. on September 18, 2018 in connection with a proposed merger, which merger was subsequently terminated in December 2018. To resolve all matters under the credit agreement and the terminated merger agreement, on October 21, 2019, CGIX entered into a settlement agreement with NovellusDx, under which CGIX paid NovellusDx $100,000 in cash, and agreed to remit $1.0 million within five business days from the date in which it received the note payment from IDXG on behalf of its affiliate described above. In addition, CGIX is required to pay NovellusDx $50,000 per month for the next subsequent nine months, or a total of $450,000, upon satisfaction of which the credit agreement and promissory note will terminate. Subject to the company making the $1 million payment, NovellusDx and CGIX each agreed to waive any and all claims against the other in connection with the credit agreement and the terminated merger agreement from December 2018, other than the remaining payments totaling $450,000.

 

On October 21, 2019, CGIX entered into a note purchase agreement with Atlas Sciences, LLC to borrow $1.25 million pursuant to an unsecured promissory note in the initial principal amount of approximately $1.35 million (with the difference representing original issue discount and expenses). The proceeds of the note, along with a cash amount of approximately $1.46 million to be provided by CGIX, will be used to repay the outstanding amount due to Iliad Research and Trading, L.P. (an affiliate of Atlas Sciences, LLC) under the promissory note issued on July 17, 2018.

 

Also on October 21, 2019, CGIX entered into an M&A Advisory Engagement with H.C. Wainwright & Co. LLC to assist CGIX with its ongoing strategic initiatives to identify and evaluate potential acquisition, merger, business combination or other strategic transaction involving CGIX. The company does not intend to discuss or disclose further developments regarding the strategic review process unless and until its Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate or required by law.

 

 
 

 

About Cancer Genetics, Inc.

 

Through the acquisition of vivoPharm in 2017, the company’s wholly owned subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. The company reported revenue from its Discovery business of $3.3 million for the six month period ended June 30, 2019 compared to $2.7 million for the six months ended June 30, 2018.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics, Inc.’s expectations regarding future financial and/or operating results, potential for our tests and services and future revenues or growth in this press release constitute forward-looking statements.

 

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks with respect to our ability to collect on future income streams and settle with our creditors, risks with respect to our ability to successfully operate the Discovery business, risks with respect to our need and ability to obtain future capital to satisfy our obligations to our lenders and creditors, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from the transactions described herein will not be realized, uncertainties with respect to evaluating strategic options, maintenance of intellectual property rights, risks with respect to maintaining our listing on Nasdaq, and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2018 and Form 10-Q for the quarters ended March 31 and June 30, 2019, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

 

Investor Contacts:

John A. Roberts

Email: jay.roberts@cgix.com

 

-2-